acute myocardial infarction

GIANT: Evaluation of the genetic profile of CYP2C19 in patients undergoing primary angioplasty

The aim of this study was to evaluate the clinical impact resistance thienopyridines through genetic analysis of CYP2C19 receptor. The primary endpoint was &nbsp;a combination of mortality, myocardial infarction, stent thrombosis in the resistance group (few responders) versus non-resistant (responders) to the thienopyridines. 1445 patients were included of which 22% were considered few responders. There<a href="https://solaci.org/en/2015/06/24/giant-evaluation-of-the-genetic-profile-of-cyp2c19-in-patients-undergoing-primary-angioplasty/" title="Read more" >...</a>

SAVOR-TIMI 53: Saxagliptin showed no cardiovascular benefit

The cardiovascular safety and efficacy of some hypoglycemic including saxagliptin (Onglyza), an inhibitor of dipeptidyl peptidase 4 (DPP-4), is not well established. 16492 patients were randomized diagnosed with type 2 diabetes with a history of cardiovascular events or high risk to receive saxagliptin or placebo. Other medications for diabetes, including hypoglycemic, were permitted. The combined<a href="https://solaci.org/en/2015/06/24/savor-timi-53-saxagliptin-showed-no-cardiovascular-benefit/" title="Read more" >...</a>

Current hemodialysis patients show similar results for sirolimus-eluting and paclitaxel

Original title:&nbsp;Drug-eluting stents in patients on chronic haemodialysis: Paclitaxel-eluting stents vs. limus &ndash;eluting stents&nbsp;Reference: Gabriel l. Sardi, et al. Cardiovasc Revasc Med. 2014 Mar;15(2):86-91. End Stage Renal Disease (ESRD) including renal failure on hemodialysis is associated with coronary heart disease and diabetes with subsequent need for revascularization that in this special population has a high<a href="https://solaci.org/en/2015/06/01/current-hemodialysis-patients-show-similar-results-for-sirolimus-eluting-and-paclitaxel/" title="Read more" >...</a>

The ambulance is the best way to get to the hospital in case of an infraction

Only 16 per cent of patients suffering a myocardial infarction call 911 for help, stated the experts of the Semicyuc: the Spanish Medical Society of ICU (Sociedad Espa&ntilde;ola de Medicina Intensiva y Unidades Coronarias), at the ARIAM study presentation. This study branched out of a three month registry of 2,051 MI patients. From these data<a href="https://solaci.org/en/2015/06/01/the-ambulance-is-the-best-way-to-get-to-the-hospital-in-case-of-an-infraction/" title="Read more" >...</a>

TOTAL Trial: The Best on Manual Thrombectomy in AMI Patients

Original title:&nbsp;Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy.&nbsp;Reference:&nbsp;S.S. Jolly et al. for the TOTAL Investigators. N Engl J Med. 2015 Apr 9;372(15):1389-98. Manual thrombectomy is a routine procedure with ST elevation AMI patients. This common practice proved to reduce mortality in the TAPAS study. However, the TASTE study did not observe<a href="https://solaci.org/en/2015/05/20/total-trial-the-best-on-manual-thrombectomy-in-ami-patients/" title="Read more" >...</a>

Risks and benefits of extending dual antiplatelet therapy in patients with and without MI

Original title:&nbsp;Benefits and Risks of Extended Duration Dual Antiplatelet Therapy after PCI in Patients With and Without Acute Myocardial Infarction. The DAPT Study.&nbsp;Reference:&nbsp;Robert W. Yeh et al. J Am Coll Cardiol. 2015, online before print. The risks and benefits of prolonged antiplatelet therapy after PCI could be different in patients presenting with AMI compared to<a href="https://solaci.org/en/2015/04/21/risks-and-benefits-of-extending-dual-antiplatelet-therapy-in-patients-with-and-without-mi/" title="Read more" >...</a>

CTO revascularization is beneficial

T&iacute;tulo original:&nbsp;Long-Term Survival Benefit of Revascularization Compared UIT Medical Therapy in Practice UIT Coronary Chronic Total Occlusion and Well-Developed Collateral Circulation.&nbsp;Reference:&nbsp;Woo Jin Jan, el at. J Am Coll Cardiol Interv 2015;8:271-9 Multiple studies have shown the benefit of chronic total occlusion (CTO) revascularization, but for patients presenting Rentrop 3 grade collateral circulation (CC), such benefit<a href="https://solaci.org/en/2015/03/24/cto-revascularization-is-beneficial/" title="Read more" >...</a>

The MGuard stent shows a trend toward reduced mortality in PCI

Original title:&nbsp;Mesh-Covered Embolic Protection Stent Implantation in ST-Segment&ndash;Elevation Myocardial Infarction. Final 1-Year Clinical and Angiographic Results From the MGUARD for Acute ST Elevation Reperfusion Trial.&nbsp;Reference:&nbsp;DariuszDudek et al. CircCardiovascInterv. 2015 Feb;8(2). &nbsp; The MGuard is a micronet mesh-covered stent designed to reduce distal embolization in the context of ST elevation myocardial infarction. In the MASTER study<a href="https://solaci.org/en/2015/02/23/the-mguard-stent-shows-a-trend-toward-reduced-mortality-in-pci/" title="Read more" >...</a>

Net clinical benefit of bivalirudin in STEMI patients

Original title:&nbsp;Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: Pooled Patient-Level Analysis From the HORIZONS-AMI and EUROMAX Trials.&nbsp;Reference:&nbsp;Stone GW et al. J Am CollCardiol. 2015 Jan 6;65(1):27-38. The HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) that included 3602 STEMI patients undergoing<a href="https://solaci.org/en/2015/01/29/net-clinical-benefit-of-bivalirudin-in-stemi-patients/" title="Read more" >...</a>

Never ending controversy over the duration of post DES dual antiplatelet therapy

Original title:&nbsp;Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month &#8211; Dual Antiplatelet Therapy- The SECURITY Randomized Clinical Trial.&nbsp;Reference:&nbsp;Antonio Colombo et al. J Am CollCardiol. 2014 Nov 18;64(20):2086-97. The optimal duration of dual antiplatelet therapy after second-generation DES implantation is still debated and apparently will remain controversial for some time. The aim of this<a href="https://solaci.org/en/2015/01/15/never-ending-controversy-over-the-duration-of-post-des-dual-antiplatelet-therapy/" title="Read more" >...</a>

Top